Stoke Therapeutics Inc Forecast, price target & analysts
Stoke Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Stoke Therapeutics Inc Classifications & Recommendation
Stoke Therapeutics Inc Price Target
| Target Price | $46.92 |
| Price | $27.91 |
| Potential |
68.11%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Stoke Therapeutics Inc 2027 .
The average Stoke Therapeutics Inc target price is $46.92.
This is
68.11%
register free of charge
$63.00
125.73%
register free of charge
$35.35
26.66%
register free of charge
|
|
| A rating was issued by 20 analysts: 19 Analysts recommend Stoke Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Stoke Therapeutics Inc stock has an average upside potential 2027 of
68.11%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 184.42 | 32.70 |
| 404.43% | 82.27% | |
| EBITDA Margin | -10.20% | -763.28% |
| 96.24% | 7,379.50% | |
| Net Margin | -3.74% | -709.27% |
| 98.46% | 18,884.55% |
16 Analysts have issued a sales forecast Stoke Therapeutics Inc 2026 . The average Stoke Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Stoke Therapeutics Inc EBITDA forecast 2026. The average Stoke Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Stoke Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Stoke Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.12 | -3.72 |
| 92.73% | 3,000.00% | |
| P/E | negative | |
| EV/Sales | 46.12 |
16 Analysts have issued a Stoke Therapeutics Inc forecast for earnings per share. The average Stoke Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Stoke Therapeutics Inc...
Current Stoke Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 21 2026 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | May 11 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 21 2026 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
May 11 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
